COVID-19 UPDATE:

We look forward to welcoming you to the RAS-Targeted Drug Development Summit on September 14-16. Please see our response to the COVID-19 outbreak here.

RAS Targeted Drug Development US - Boston, MA

Finally Bring an End to RAS Driven Cancers

Explore Novel Discoveries, Identify Rational Anti-RAS Combination Strategies & Accelerate the Translation of Next Generation Mutant-Targeted RAS Therapies into Human Clinical Trials

As the first KRAS inhibitors reach the clinic and show promising opportunities to address unmet clinical need, the 2nd RAS- Targeted Drug Development Summit 2020 returns to drive forward the clinical translation of first generation Anti-RAS therapies.

The two-track 2nd RAS- Targeted Drug Development Summit 2020 will be your comprehensive and definitive platform, dedicated to bringing together the largest community of RAS experts from large pharma, innovative biotech and research institutes to capitalize on the emerging therapeutic opportunities to finally bring an end to RAS driven cancers.

 

What You Can Expect:

RAS Key Stats

Expert Speakers Include:

Frank McCormick

Professor & Leader NCI RAS Initiative

Frederick National Laboratory for Cancer Research

Channing Der

Sarah Graham Kenan Distinguished Professor

University of North Caroline at Chapel Hill

Steve Kelsey

President R&D

Revolution Medicines

Peter Hammerman

Global Head of Translational Oncology

Novartis

Lusong Luo

Senior Vice President, External Innovation

Beigene

Marie Evangelista

Senior Scientist & Project Team Lead, Discovery Oncology

Genentech

Proud to Partner With:

Other Events In The Undruggable Series